FYI, I just saw this was published on Pubmed. I think it is actually the first head-to-head study comparing Zometa (zoledronic acid) with Aredia (pamidronate) as to which is the better bisphosphonate.
I took Aredia for a year, so maybe Zometa would have been better. See:
"Comparative Effectiveness on Survival of Zoledronic Acid versus Pamidronate in Multiple Myeloma", Leuk Lymphoma. 2014 May 21:1-22.
Abstract:
Zoledronic acid and pamidronate are the two bisphosphonates approved to reduce multiple myeloma skeletal complications in the United States. Little prior evidence exists comparing survival outcomes between the two. We evaluated the incidence of skeletal related events and overall survival in myeloma patients treated with zoledronic acid versus pamidronate using a cohort of 1,018 United States Veterans. At median follow-up of 26.9 months, patients receiving zoledronic acid had a 22% reduction in risk of death compared to pamidronate (hazard ratio (HR) 0.78; 95% CI, 0.67-0.92). The benefit persisted after controlling for potential confounders. Adjusted Cox modeling with inverse probability weighting and propensity score matching supported these findings. Zoledronic acid was also associated with a 25% decrease in skeletal-related events. Zoledronic acid is associated with increased overall survival and decreased skeletal related events compared to pamidronate in patients with multiple myeloma and should become the preferred bisphosphonate.
http://www.ncbi.nlm.nih.gov/pubmed/24844358
Forums
3 posts
• Page 1 of 1
-
terryl1 - Name: Terry
- Who do you know with myeloma?: self
- When were you/they diagnosed?: August 10, 2011
- Age at diagnosis: 49
Re: New Zometa versus Aredia study
Thanks for pointing this out Terry.
There are more details about this study available in an abstract that was reported at the 2013 ASH meeting. Here's a link to the abstract:
Zoledronic Acid Improves Overall Survival Compared To Pamidronate In Multiple Myeloma
This study was not actually a head-to-head comparison of Zometa versus Aredia. It's a retrospective analysis based on the identification of patients that had been treated with one drug or the other.
In a true head-to-head clinical trial, patients are randomly assigned to receive one drug or the other. That was not the case here.
The patients in this study were put on Zometa or Aredia because they and their doctors decided to put them on that drug after considering all the alternatives. We don't know the reason why those decisions were made the way they were. But the process wasn't random.
There are more details about this study available in an abstract that was reported at the 2013 ASH meeting. Here's a link to the abstract:
Zoledronic Acid Improves Overall Survival Compared To Pamidronate In Multiple Myeloma
This study was not actually a head-to-head comparison of Zometa versus Aredia. It's a retrospective analysis based on the identification of patients that had been treated with one drug or the other.
In a true head-to-head clinical trial, patients are randomly assigned to receive one drug or the other. That was not the case here.
The patients in this study were put on Zometa or Aredia because they and their doctors decided to put them on that drug after considering all the alternatives. We don't know the reason why those decisions were made the way they were. But the process wasn't random.
-
Multibilly - Name: Multibilly
- Who do you know with myeloma?: Me
- When were you/they diagnosed?: Smoldering, Nov, 2012
3 posts
• Page 1 of 1
Return to Treatments & Side Effects